Neoantigen Prediction for Precision Immunotherapies 

Learn about the tools and resources researchers use to define, discover, and deploy anti-tumor immunotherapies.

 LIVE Symposium

Friday, February 24, 2022
11:00 AM - 2:00 PM Eastern Time

Researchers develop immunotherapies based on cancer mutations that produce neoantigens. These proteins are unique to tumors and facilitate immune system activation. Researchers predict neoantigens using sequencing methodologies and develop modified immune cells including T cells, NK cells, and dendritic cells. 

In this symposium brought to you by The Scientist’s Creative Services Team, researchers will highlight tools and resources used to hunt for neoantigens and discuss how neoantigen T cell receptors (TCRs) are proving effective in destroying tumors.

Symposium program

11:00 AM – Introduction

11:10 AM – Hitting the target: endogenous T cell responses to pediatric tumor neoantigens

Paul Thomas, PhD

11:45 AM – Drugging intracellular targets with antibodies

David Scheinberg, MD, PhD

12:20 PM – Understanding the fate of neoantigen-specific T cells in cancer

Ingunn Stromnes, PhD

12:55 PM – TBD

1:30 PM - Open panel Q&A session
Deanna MacNeil from The Scientist's Creative Services Team will be joined by the entire panel in an open question and answer session where presenters will address questions posed by the audience.


Paul Thomas, PhD
Member, St. Jude Faculty
Immunology Department
Comprehensive Cancer Center
St. Jude Graduate School of Biomedical Sciences
St. Jude Children’s Research Hospital

Jie Sun 

David Scheinberg, MD, PhD
Chairman, Center for Experimental Therapeutics
Deputy Director for Therapeutic Discovery
Sloan Kettering Institute
Memorial Sloan Kettering Cancer Center

Ingunn Stromnes, PhD
Assistant Professor
Microbiology and Immunology
University of Minnesota

Sponsored by